One study found that patients with metastatic cancers that showed no response to IL-2 treatment had significantly higher ICOS+ Tregs, an especially proliferative and immunosuppressive subset, than patients who responded to treatment (81). The gene discussed is IL2; the disease is metastatic malignant neoplasm.